Athira Pharma

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOTHELL, Wash., June 07, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the formation of a Scientific Advisory Board (SAB) comprised of renowned leaders in neurology and neurodegenerative disease research – Drs. John Olichney, Anton Porsteinsson, Marwan Sabbagh, Lon Schneider, Pierre Tairot and Paul Winner. The SAB, chaired by Athira Chief Medical Officer, Dr. Hans Moebius, will offer expert scientific and clinical perspectives to guide the ongoing development of Athira's pipeline of novel, small molecule compounds.

Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Athira Pharma, Inc. (NasdaqGS: ATHA). On June 17, 2021, the Company disclosed that the Board of Directors had placed President and Chief Executive Officer Leen Kawas “on temporary leave pending a review of actions stemming from doctoral research [Kawas] conducted while at Washington St

ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of long-term stockholders following a class action complaint that was filed against Athira on June 25, 2021 with a Class Period from September 17, 2020 through June 17, 2021. Our investigation concerns whether the board of directors of Athira have breached their fiduciary duties to the company. Cli

ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

BOTHELL, Wash., May 19, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced, based on the preliminary vote count provided by its proxy solicitor, that Athira's shareholders have approved the election of all three of Athira's highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – to the company's board of directors.

Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting

Athira Board Unanimously Recommends Shareholders Vote “FOR” its Highly Qualified Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card

Athira Issues Statement in Response to Richard A. Kayne's Suspension of His Proxy Contest

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira” or the “Company”), today issued the following letter to Athira shareholders. May 16, 2022 Dear Fellow Shareholders, I started my campaign for change at Athira Pharma, Inc. in February 2022, nominating myself and George Bickerstaff, to the Athira Board of Directors because I believe in th

Ric Kayne Suspends Campaign to Elect Himself and George Bickerstaff to Athira Pharma Board of Directors

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira” or the “Company”), today issued a letter to Athira shareholders outlining numerous, value-destructive missteps by the current Board of Directors (the “Board”), and detailing why immediate change to the Board at the 2022 annual meeting of stockholders is necessary to restore shareholder v

Ric Kayne Issues Letter to Athira Shareholders Highlighting Need for Immediate Change to Athira Board

Urges Shareholders to Vote TODAY “FOR” Athira's Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card

Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting

ATHIRA PHARMA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA

Joins Institutional Shareholder Services in Recommending a Vote on Athira's WHITE Proxy Card

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira's Highly Qualified Director Nominees

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira” or the “Company”), today announced that Institutional Shareholder Services Inc. (“ISS”), the nation's leading independent proxy advisory firm, has recommended that Athira shareholders vote to “WITHHOLD” support for incumbent directors Joseph Edelman and John M. Fluke Jr. in connection wi

Leading Proxy Advisory Firm ISS Recommends Athira Shareholders “Withhold” Support From Incumbent Directors Joseph Edelman and John Fluke

Athira Urges Shareholders to Vote “FOR” Athira's Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card Today

Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira's WHITE Proxy Card

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira” or the “Company”), today issued the following statement regarding the urgent need for Athira's Board of Directors (the “Board”) to immediately commence a search process to find a qualified chief executive officer with clinical trial experience in order to improve the likelihood of succes

Ric Kayne Identifies Highly Qualified CEO Candidate for Athira

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira” or the “Company”), today mailed a letter to Athira shareholders outlining the numerous, value destructive missteps by the current Board of Directors (the “Board”), and detailing why immediate change on the Board is necessary to restore shareholder value. Mr. Kayne today also released a v

Ric Kayne Issues Letter to Athira Shareholders Highlighting Why Immediate Board Change Is Required

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira” or the “Company”), today released a detailed presentation to Athira's shareholders demonstrating the need for immediate change on the Company's Board of Directors (the “Board”) to properly oversee the clinical trials for ATH-1017 and preserve the value of shareholders' investment. The pr

Ric Kayne Publishes Investor Presentation Highlighting Urgent Need for Changes to Athira's Board of Directors

Urges shareholders to vote “FOR” Athira's highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card

Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of long-term stockholders following a class action complaint that was filed against Athira on June 25, 2021 with a Class Period from September 17, 2020 to June 17, 2021. Our investigation concerns whether the board of directors of Athira have breached their fiduciary duties to the company. On June

ATHIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira” or the “Company”), today filed a definitive proxy statement with the Securities and Exchange Commission for the election of himself and George Bickerstaff, III, the former Chief Financial Officer of Novartis Pharma AG, to Athira's Board of Directors at the Company's 2022 Annual Meeting o

Ric Kayne Files Definitive Proxy Materials for Athira's 2022 Annual Meeting

Athira Files Definitive Proxy Statement and Mails Letter to Shareholders

BOTHELL, Wash., March 30, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today issued the following statement in response to the release from Richard Kayne:

Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future

Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.

Is Athira Pharma, Inc. (ATHA) Outperforming Other Medical Stocks This Year?

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira” or the “Company”), today confirmed that he has nominated himself and George W. Bickerstaff, III, the former Chief Financial Officer of Novartis Pharma AG, for election to Athira's Board of Directors (the “Board”) at the upcoming 2022 Annual Meeting of Shareholders. Mr. Kayne issued the f

Ric Kayne and Affiliates Confirm Nomination of Two Highly Qualified Candidates for Election to Athira Pharma's Board of Directors

Athira Pharma, Inc. (ATHA) CEO Mark Litton on Q4 2021 Results - Earnings Call Transcript

On track to report topline data from ACT-AD Phase 2 Alzheimer's disease study in 2Q22

Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update

Industry Veteran Brings More than 20 Years of Experience in CNS Drug Development and Commercialization Industry Veteran Brings More than 20 Years of Experience in CNS Drug Development and Commercialization

News for Athira Pharma Stock (ATHA)